#Israel #Carmiel #Protalix #iAccess Alpha #Conference 2025

Protalix BioTherapeutics: Innovating for Tomorrow

Protalix BioTherapeutics, Inc. (NYSE American: PLX) is making waves in the biopharmaceutical industry with its groundbreaking approaches to developing and producing therapeutic proteins. Based in Carmiel, Israel, the company has pioneered a unique plant cell-based protein expression system known as ProCellEx®. This system has garnered attention not only for its innovative techniques but also for its ability to generate recombinant therapeutic proteins at an industrial scale.

This March, Protalix will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025, scheduled for March 25-26, 2025. This event will showcase companies that have been recommended by investors, providing a platform for firms like Protalix to engage with potential investors. The conference will kick off with live webcast presentations on Day 1, followed by one-on-one meetings on Day 2 between Protalix's management and selected investors.

Conference Details

The live presentation from Protalix will take place on Tuesday, March 25, 2025, at 12:00 PM EDT. Participants are encouraged to log in 15 minutes prior to the start time to ensure they have the necessary audio software installed. After the presentation, a replay will be available for six months, allowing attendees to revisit the insights shared during the event. The conference highlights include:

• - Date: March 25, 2025
• - Time: 12:00 PM EDT
• - Access Links:

- Company presentation: Protalix Event Page
- Webcast: Webcast Link

A Leader in Biopharmaceuticals

Protalix is recognized as the first company to receive FDA approval for a protein produced through a plant cell-based suspension expression system. One of its notable products is taliglucerase alfa, licensed to Pfizer Inc. for treating Gaucher disease. This partnership highlights Protalix's commitment to addressing significant health challenges through innovative solutions.

In addition, Protalix's portfolio includes Elfabrio®, a drug that received FDA and EMA approval in May 2023. This medication exemplifies the company’s advanced capabilities in creating complex biopharmaceuticals through their ProCellEx system. The collaboration with Chiesi Farmaceutici S.p.A. for the global development of Elfabrio further solidifies Protalix's place in the biopharmaceutical landscape.

Innovative Pipeline

Protalix's development pipeline is replete with promising candidates targeting various established pharmaceutical markets. Among them are:

• - PRX-115: A recombinant PEGylated uricase aimed at treating uncontrolled gout.
• - PRX-119: A long-acting DNase I designed to address NETs-related diseases.

These product candidates reflect Protalix's strategic focus on innovative treatments that cater to unmet medical needs, thereby promising a brighter future for patients worldwide.

Join Us at the iAccess Alpha Conference

The iAccess Alpha Virtual Best Ideas Spring Conference presents a unique opportunity for investors to discover and learn more about Protalix and its groundbreaking work. As the company prepares for this important event, it invites potential investors to join the conference, understand its pioneering technologies, and explore investment opportunities.

For registration and further details about the iAccess Alpha Virtual Best Ideas Spring Conference 2025, please visit the official conference website at iAccess Alpha.

As Protalix BioTherapeutics continues to chart new paths in biopharmaceutical research and development, it remains committed to innovation, collaboration, and meeting the healthcare challenges of today and tomorrow.